Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Prospective Blood Draw Clear all

Conditions: Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions: Nivolumab, Pembrolizumab; Biological
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2037
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acute Myeloid Leukemia
Interventions: Mylotarg; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 59
States / cities: Tucson, Arizona • Berkely, California • Burbank, California + 49 more

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Septic Shock, Endotoxemia
Interventions: Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge; Device
Lead sponsor: Spectral Diagnostics (US) Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 16 more

Conditions: Knee Cartilage Defects
Interventions: CARTISTEM® + Debridement, Debridement; Biological · Procedure
Lead sponsor: Medipost, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 37
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 30 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Continuous Glucose Monitoring System; Device
Lead sponsor: Senseonics, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Escondido, California • Idaho Falls, Idaho • San Antonio, Texas + 1 more

Conditions: Pregnancy
Interventions: Babyscripts Prenatal App, Placebo; Device
Lead sponsor: Andrew Meltzer; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Follicular Lymphoma
Interventions: cfDNA testing, sample of saliva or fingernail clipping, pre-treatment test specimen, PET/CT, CT, or MRI testing; Diagnostic Test · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions: Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Panitumumab; Drug · Other · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Duarte, California • Lancaster, California • Rancho Cucamonga, California + 1 more

Conditions: Multiple Myeloma, Plasma Cell Neoplasm
Interventions: chemoprotection, complementary or alternative medicine procedure, management of therapy complications; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Streptococcus Agalactiae Infection
Interventions: Comparison between GenePOC PCR and Reference Method; Device
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 771 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Detroit, Michigan • Albuquerque, New Mexico

Conditions: Breast Cancer
Interventions: Blood Sample; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphedema, Edema
Interventions: Biobridge and lymph node transfer; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hemorrhage
Interventions: Kcentra®, Plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 2,238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
Interventions: ABT-335, Atorvastatin, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Colorectal Cancer
Interventions: Fecal immunochemical test; Other
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • New York, New York

Conditions: Diabetic Foot Ulcer, Offloading
Interventions: Offloading boot: PulseFlow; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Poor Glycemic Control
Interventions: Metformin, Glargine insulin, Glulisine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Dysphagia, Achalasia
Interventions: Amyl Nitrite; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Metastatic Breast Cancer, HR+ HER2 Breast Cancer, Metastatic Triple Negative Breast Cancers, Metastatic Triple-Negative Breast Carcinoma
Interventions: Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review; Procedure · Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • The Bronx, New York • Durham, North Carolina

Conditions: Hypotension During Surgery, Blood Loss, Surgical
Interventions: Avoidance of Deliberate Hypotensive Anesthesia, TRANEXAMIC ACID 1 G in 10 mL INTRAVENOUS INJECTION, SOLUTION; Other · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years to 75 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Ovarian Cancer
Interventions: Vitamin D3; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Mastectomy
Interventions: Application of autologous blood products., Standard Modified Radical Mastectomy; Procedure
Lead sponsor: Marshall University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Pleuropulmonary Blastoma
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 80
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more

Search by objective public record fields.

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis

Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features

Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study

Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma

Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains

Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer

Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

FITting Non-invasive Tests in Lynch Syndrome Surveillance

Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study

Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients

Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM)

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery

Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer

Application Of Autologous Blood Products During Modified Radical Mastectomy

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma